For the quarter ending 2025-09-30, ARCT made $17,151,000 in revenue. -$13,448,000 in net income. Net profit margin of -78.41%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenue | 17,151,000 | 28,301,000 | 29,382,000 | 36,879,000 |
| Research and development, net | 23,265,000 | 29,579,000 | 34,893,000 | 52,007,333.333 |
| General and administrative | 10,398,000 | 10,338,000 | 11,315,000 | 13,182,333.333 |
| Total operating expenses | 33,663,000 | 39,917,000 | 46,208,000 | 65,189,666.667 |
| Loss from operations | -16,512,000 | -11,616,000 | -16,826,000 | -28,310,666.667 |
| Loss from foreign currency | -170,000 | -127,000 | -21,000 | -90,000 |
| Finance income, net | 3,234,000 | 2,567,000 | 2,771,000 | 3,792,333.333 |
| Net loss before income taxes | -13,448,000 | -9,176,000 | -14,076,000 | -24,608,333.333 |
| Provision (benefit) for income taxes | - | 4,000 | - | 71,000 |
| Net loss | -13,448,000 | -9,180,000 | -14,076,000 | -24,679,333.333 |
| Comprehensive loss | -13,448,000 | -9,180,000 | -14,076,000 | -24,679,333.333 |
| Basic | -0.49 | -0.34 | -0.52 | -0.913 |
| Basic | 27,188,000 | 27,129,000 | 27,107,000 | -20,666.667 |
| Diluted | -0.49 | -0.34 | -0.52 | -0.913 |
| Diluted | 27,188,000 | 27,129,000 | 27,107,000 | -20,666.667 |
Arcturus Therapeutics Holdings Inc. (ARCT)
Arcturus Therapeutics Holdings Inc. (ARCT)